Michael J. Smith
14Patents
4h-index
67Co-inventors
63Inventor score
Filing activity: Aug 10, 1998 → Dec 22, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7728027B2 | Process for synthesizing compounds useful for treating hepatitis C | Human Necessities | 34 | Active |
| US8377980B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 21 | Active |
| US8969529B2 | Methods and compositions based on shiga toxin type 2 protein | Emerging Cross-Sectional Technologies | 19 | Active |
| US7521473B2 | Inhibitors of protein tyrosine phosphatase 1B | Chemistry; Metallurgy | 17 | Active |
| US8293245B2 | Methods and compositions based on Shiga toxin type 1 protein | Chemistry; Metallurgy | 4 | Active |
| US8846058B2 | Shiga toxoid chimeric proteins | Emerging Cross-Sectional Technologies | 3 | Active |
| US6268407A | Compositions and articles of manufacture | Chemistry; Metallurgy | 3 | Expired |
| US6600030B2 | Delayed progression to aids by a missense allele of the CCR2 gene | Chemistry; Metallurgy | 2 | Expired |
| US9801931B2 | Methods and compositions based on Shiga toxin type 2 protein | Emerging Cross-Sectional Technologies | 2 | Active |
| US10899745B2 | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide | Chemistry; Metallurgy | 1 | Active |
| US11623013B2 | Methods and compositions for deuterated biologics | Human Necessities | 0 | Active |
| US6245575A | Screening of agents for treatment of alzheimer's disease | Emerging Cross-Sectional Technologies | 0 | Expired |
| US7674822B2 | PTP1b inhibitors | Chemistry; Metallurgy | 0 | Active |
| US12410254B2 | Treatment of cardiometabolic disease with inhibitors of type I interferon signalling | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.